AbbVie adds Boehringer Ingelheim’s BI 655066 to its Autoimmune Portfolio
By Natasha Berry
Pharma Deals Review: Vol 2016 Issue 3 (Table of Contents)
Published: 24 Mar-2016
DOI: 10.3833/pdr.v2016.i3.2149 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
To add to its autoimmune therapy area, which is currently dominated by the multi-blockbuster Humira® (adalimumab), AbbVie has entered into a global collaboration with Germany based Boehringer Ingelheim (BI) for the development and commercialization of BI’s Phase III psoriasis asset, risankizumab (BI 655066)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS